Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy

doi:10.3748/wjg.v23.i2.306

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9953)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

587

WORD

347

HTML

4148

Figures (1-3)

290

Tables (1-4)

250

Sum=5622

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

598

Download

1046

Sum=1644

Publishing Process of This Article

Item

Count

Browse

919

Download

1768

Sum=2687

Jan 14, 2017 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jan 14, 2017; 23(2): 306-317
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.306

Table 1 Characteristics of the modified intent-to-treat population

Characteristic	Vacc. (n = 107)	Ctr. (n = 115)	P value
Demographics
Age, median (IQR)	28.9 (23.1-37.1)	29.3 (24.0-35.4)	0.950
Male sex, n (%)	86 (78.9)	86 (74.1)	0.400
Weight (kg), median (IQR)	62.5 (56.0-70.0)	63.0 (56.0-70.0)	0.907
Genotype B, n (%)	42/107 (39.3)	39/115 (33.9)	0.409
Week 0 laboratory results
ALT (IU/L), median (IQR)	119.0 (94.0-167.5)	136.0 (102.6-195.3)	0.066
HBV DNA (log₁₀ IU/mL), median (IQR)	8.1 (7.7-8.3)	8.1 (7.5-8.4)	0.953²
HBeAg (COI), median (IQR)	852.0 (223.5-1093.0)	926.6 (508.5-1076.0)	0.197²
HBsAg (IU/mL), median (IQR)	10261.0 (3953.0-24089.0)	8637.0 (2748.0-24436.0)	0.754²
Week 12 laboratory results¹
HBV DNA (log₁₀ IU/mL), median (IQR)	3.5 (2.6-4.5)	3.4 (2.6-4.6)	0.754²
HBeAg (COI), median (IQR)	147.4 (15.6-650.0)	45.9 (11.9-1011.0)	0.605²
HBsAg (IU/mL) median (IQR)	4072.0 (1608.0-8514.0)	3023.5 (1167.0-11194.0)	0.460²

¹The time point when the injection of study agent started;

²Analyzed with Wilcoxon Rank Sum test. mITT: Modified intent-to-treat; LAM: Lamivudine; IQR: Interquartile ranges; ALT: Alanine aminotransferase; COI: Semi-quantification by S/CO [the signal value ratio of sample (S) to the control (CO)]; Vacc.: LAM + vaccine arm; Ctr.: LAM + placebo arm.

Citation: Yang FQ, Rao GR, Wang GQ, Li YQ, Xie Y, Zhang ZQ, Deng CL, Mao Q, Li J, Zhao W, Wang MR, Han T, Chen SJ, Pan C, Tan DM, Shang J, Zhang MX, Zhang YX, Yang JM, Chen GM. Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol 2017; 23(2): 306-317
URL: https://www.wjgnet.com/1007-9327/full/v23/i2/306.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i2.306